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ABSTRACT 
Background and Objectives: Although electrical cardioversion (CV) is effective in restoring sinus rhythm (SR) in 
patients with atrial fibrillation (AF), AF frequently recurs in spite of antiarrhythmic medications. We investigated 
the predictors of failed CV and AF recurrence after successful CV. Subjects and Methods: In 81 patients (M:F= 
63:18, 59.1±10.5 years old) with AF who underwent CV, clinical findings and pre-CV serologic markers were 
evaluated. Results: During 13.1±10.6 months of follow-up, 8.6% (7/81) showed failed CV, 27.16% (22/81) 
showed early recurrence atrial fibrillation (ERAF; ≤2 weeks), 32.1% (26/81) had late recurrence atrial fibrillation 
(LRAF; >2 weeks), and 32.1% (26/81) remained in SR and had no recurrence (NR). Plasma levels of transforming 
growth factor beta (TGF)-β were significantly higher in patients with failed CV than in those with successful CV 
(p=0.0260). Patients in whom AF recurred were older (60.4±9.0 years old vs. 55.3±12.5 years old, p=0.0220), 
and had lower plasma levels of stromal cell derived factor (SDF)-1α (p=0.0105). However, there were no significant 
differences in these parameters between ERAF patients and LRAF patients. Conclusion: Post-CV recurrence com-
monly occurs in patients aged >60 years and who have low plasma levels of SDF-1α. High plasma levels of TGF-β 
predict failure of electrical CV. (Korean Circ J 2010;40:185-190) 
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Introduction 
 
Atrial fibrillation (AF) is the most common cardiac 
arrhythmia in clinical practice. It leads to significant 
morbidity and disability and results in a low quality of 
life.1) It has been reported that appropriate rhythm con-
trol may reduce mortality in patients with AF.2) Alth-
ough electrical cardioversion (CV) is known to be effec-
tive in restoring sinus rhythm (SR) in patients with 
persistent AF (PeAF), AF frequently recurs in spite of 
concomitant medication with antiarrhythmic drugs.3)4) 
Approximately 50% of patients who successfully cardio-
vert initially experience AF recurrence within the first 
month after CV.5)6) This is due to significant electrical 
remodeling,7)8) structural changes in the atrial myocar-
dium in patients with AF,9) and the limitations of anti-
arrhythmic drugs.2)3)5) Although there have been several 
reports,11)12) the predictors of successful CV or long-term 
maintenance of SR in patients with PeAF are not yet 
clear. The development of serological predictors for re-
currence after CV may reduce the number of unnecess-
ary procedures, the risk of complications and medical 
costs, and may improve the clinical outcome of highly 
selected patients. Discovering predictors for post-CV 
recurrence would also contribute to our understand-
ing of AF pathophysiology. Therefore, we investigated 
whether certain parameters related to matrix remodel-
ing, fibrosis, atrial stretching, and chemotaxis, can pre-
dict failure or recurrence of AF after electrical CV. 
 
Subjects and Methods 
 
Study population 
This study was approved by the Institutional Review 
Board of Anam Hospital of Korea University. All patients 
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provided written informed consent. Eighty-one patients 
with PeAF (male:female=63:18, mean age 59.1±10.5 
years old) who underwent external electrical CV were 
included in the study. We excluded patients with a his-
tory of any previous CV, significant mitral valvular 
heart disease, a huge left atrium (LA; > 55 mm), a recent 
infection, surgery or acute coronary syndrome in the 2 
months prior to the collection of blood samples. All pa-
tients maintained optimal anticoagulation, had been 
taking anti-arrhythmic drugs for at least 1 month, and 
maintained them after CV. Transesophageal echocar-
diography was done to exclude an intra-cardiac throm-
bus on the same day of CV in every patient. The blood 
samples for the serologic assays were drawn before seda-
tion for external CV. 
 
Electrical cardioversion protocol 
After obtaining written informed consent, electrical 
CV was performed under sedation with intravenous 
midazolam (0.05 mg/kg) and thiopental sodium (60 
mg/kg). A biphasic R wave synchronized shock (Life-
pak12, Physiocontrol Ltd. Redmond, WA, USA) was 
applied to the patients via self-adhesive skin electrodes 
(TZ Medical Inc., Portland, OR, USA) in an anterior-
posterior position. We delivered an initial CV with 70 J. 
If the initial shock failed to terminate AF, the biphasic 
shock energy was gradually increased to 100 J, 150 J, and 
then 200 J serially (5 minutes intervals). If CV terminat-
ed AF successfully, the patient’s cardiac rhythm was mo-
nitored for 15 minutes to detect an atrial premature beat 
(APC) or recurrence of AF. If AF returned within 15 mi-
nutes of termination of CV, amiodarone 150 mg was ad-
ministered intravenously and the same energy shock was 
repeated. Patients in whom AF remained even after be-
ing given a 200 J CV or who exhibited repeated imme-
diate recurrence of AF in spite of amiodarone were de-
fined as failed CVs. 
 
Biochemical analyses 
We acquired a 5 mL sample of peripheral blood im-
mediately before CV to measure the plasma levels of se-
veral protein markers or chemokines by enzyme linked 
immuno-sorbent assay: pro-atrial natriuretic peptide 
(ANP; Biomedica, Antony, France), matrix metallopro-
teinase (MMP)-9, transforming growth factor (TGF)-β, 
and stromal cell derived factor (SDF)-1α (R&D Sys-
tems, Minneapolis, MN, USA). High sensitivity C-re-
active protein (hs-CRP) was measured on a Hitachi 912 
assay system (Roche Diagnostics, Indianapolis, IN, USA) 
using a Kamiya K-assay (Kamiya Biomedical Corp., Seat-
tle, WA), which quantitatively determines CRP by a latex 
particle-enhanced immuno-turbidimetric assay. 
 
Follow-up of patients 
After CV, all patients were prospectively followed up 
at an outpatient clinic at 1, 2, 4, 8 weeks, and then 
every 3 months thereafter. Elecrocardiography (ECG) 
was performed at every visit or anytime the patient re-
ported palpitations. A Holter ECG (24 hours or 48 
hours) and/or event recorder was evaluated at 2 months 
in patients who did not experience recurrence. We clas-
sified patients into 4 different groups according to cli-
nical outcome as follows: 1) failed CV, 2) early recurr-
ence of AF (ERAF; within 2 weeks), 3) late recurrence 
of AF (LRAF; after 2 weeks), and 4) no recurrence (NR) 
after 2 months. 
 
Statistical analysis 
We evaluated the clinical factors {e.g., age, sex, LA size, 
ejection fraction (EF), spontaneous echo contrast (SEC)} 
and serologic factors (MMP-9, SDF-1α, TGF-β, pro-
ANP, and hs-CRP) in terms of success or failure of CV 
and the timing of recurrence. Comparisons between gr-
oups were analyzed by the Mann-Whitney test or a t-test. 
In order to identify the predictors of failed CV or the re-
currence of AF after successful CV, uni-variate and mul-
tivariate logistic regression analyses were performed. AF 
free rates were compared in terms of clinical, electrophy-
siological, and serological parameters by utilizing Kaplan-
Meier curves. We chose cutoff numbers that were simi-
lar to the mean that divided 2 groups with similar num-
bers of the patients. All values are expressed as mean± 
SD. All statistical analyses were performed using Statis-
tical Package for the Social Sciences (SPSS) version 12.0 
and a p<0.05 was considered statistically significant. 
 
Results 
 
Patient characteristics and clinical outcomes 
We performed external electrical CV in 81 patients 
(59.1±10.5 years old, 63 males) with PeAF or perma-
nent AF. The mean LA size was 45.5±6.0 mm, and 
the mean EF of the LV was 48.7±15.1%. All patients 
had been taking antiarrhythmic drugs for at least 1 
month before and after CV (amiodarone 60.5%, other 
class IC anti-arrhythmic drugs 39.5%). The mean num-
ber of electrical shocks performed was 1.9±1.4, the 
final successful CV energy was 96.7±32.3 J, and the 
cumulative CV energy was 170.4±178.5 J. Among the 
81 patients, 8.6% (7/81) showed failed CV and 91.4% 
(74/81) underwent successful CV. We followed up the 
74 patients after their successful CV for an average of 
13.2±11.0 months. Of the 74, 22 (29.7%) showed AF 
recurrence within 2 weeks (ERAF), 26 (35.1%) after 2 
weeks (LRAF), and 26 (35.1%) remained in SR and had 
NR during the follow-up period.  
 
Serological predictors for failed electrical  
cardioversion 
Table 1 summarizes comparisons of the clinical and 
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biochemical parameters in patients with successful and 
failed electrical CV. There were no significant differences 
in age, sex, LA size, EF, the existence of SEC, or medi-
cations. However, the prescription rate of amiodarone 
was lower in patients with failed CV compared to those 
with successful CV (28.6% vs. 64.9%, p=0.0301). Both 
the final energy (121.4±26.7 J vs. 93.7±31.8 J, p=0.0154) 
and the incidence of the requirement of intravenous 
amiodarone (100% vs. 14.9%, p<0.0001) were higher 
in patients with failed CV. The pre-CV plasma level of 
TGF-β, which reflects the degree of fibrosis, was signi-
ficantly higher in patients with failed CV (22.7±22.9 
ng/mL) than in those with successful CV (13.5±9.8 
ng/mL, p=0.0260).  
 
Predictors for recurrence after successful 
cardioversion 
The recurrence rate of AF after successful CV was 
64.9% (48/74) during the 13.2±11.0 months follow-
up. Table 2 summarizes comparisons of clinical, elec-
trophysiological, and serological parameters. The patients 
who showed recurring AF after CV were older than those 
without recurrence (60.4±9.0 years old vs. 55.3±12.5 
years old, p=0.0220). There was no significant differ-
ence in either LA size or EF. Pre-CV plasma levels of 
SDF-1α (3.2±1.2 ng/mL vs. 3.9±0.8 ng/mL, p= 
0.0105) were significantly lower in patients with recur-
rent AF than in those without recurrence. In univari-
ate logistic regression analyses, it was found that old 
age {odds ratio (OR) 1.053, 95% confidence interval (CI) 
1.004-1.053, p=0.035} and lower SDF-1α (OR 0.603, 
95% CI 0.379-0.960, p=0.033) may predict the recur-
rence of AF after successful CV. In multivariate logistic 
regression analysis, low SDF-1α (OR 0.537, 95% CI 
0.302-0.954, p=0.034) was an independent risk factor 
for AF recurrence after successful CV. In Kaplan-Me-
ier analyses, the AF recurrence rate was higher in pa-
tients who were older than 60 (p=0.0295) and had pla-
sma SDF-1α <3.0 ng/mL (p=0.0114) (Fig. 1). 
 
Timing of recurrence 
Among 48 patients whose AF recurred during the 
follow-up period after successful CV, 45.8% (22/48) 
recurred within 2 weeks (ERAF), while 54.2% (26/48) 
recurred after 2 weeks (LRAF) (Table 3). The mean time 
to LRAF was 85.5±134.7 days. However, we failed to 
find a significant difference in clinical and serological 
parameters between ERAF and LRAF groups (Table 3). 
 
Left atrium size dependent factors 
We compared patients with LA ≥45 mm to those 
with LA <45 mm. In patients with LA ≥45 mm, the 
incidence of SEC (69.8% vs. 45.5%, p=0.0164) was 
higher. However, the failure rate of CV and the recurr-
Table 1. Comparison of patients with failed CV and successful
CV 
 
Failed CV 
(n=7) 
Successful CV 
(n=74) p 
Male (%) 085.71 77.03 <0.3013
Age (years) 63.71±8.50 58.62±10.58 <0.1104
LA size (mm) 42.53±6.90 45.76±5.90 <0.1037
EF (%) 44.73±24.36 49.13±14.12 <0.2326
SEC (%) 050.00 58.33 <0.3480
Amiodarone (%) 028.60 64.90 <0.0301
J final 121.4±26.7 93.73±31.83 <0.0154
IRAF (%) 071.43 04.05 <0.0001
IV AAD (%) 100.00 14.86 <0.0001
APC (%) 028.57 56.16 <0.0830
Bradycardia (%) 000.00 04.29 <0.2911
MMP-9 (ng/mL) 89.77±41.27 123.13±62.80 <0.0882
SDF-1α (ng/mL) 3.64±1.09 3.47±1.14 <0.3519
TGF-β (ng/mL) 22.68±22.92 13.48±9.84 <0.0260
Pro-ANP (nmol/L) 6.62±3.56 5.54±4.32 <0.2624
hs-CRP (ng/mL) 3.68±6.21 4.18±11.71 <0.4559
Recurrence (%) 100.00 64.38 <0.0380
CV: cardioversion, LA: left atrium, EF: ejection fraction, SEC: sp-
ontaneous echo contrast, J final: final CV energy (J), IRAF: imme-
diate recurrence of AF after CV, AAD: anti-arrhythmic drug, APC:
atrial premature contractions, MMP-9: matrix metalloproteinase-9, 
SDF-1α: stromal cell derived factor-1α, TGF-β: transforming gr-
owth factor-β, ANP: atrial natriuretic peptide, hsCRP: high sen-
sitive-C reactive protein, AF: atrial fibrillation 
 
Table 2. Comparison of patients with recurrence of AF and no 
recurrence of AF after successful CV 
 
Recurrence 
(n=48) 
No recurrence
(n=26) p 
Male (%) 81.25 69.23 0.1233
Age (years) 60.44±8.99 55.27±12.52 0.0220
LA size (mm) 46.15±5.08 45.05±6.63 0.2286
EF (%) 48.93±14.51 49.50±13.67 0.4346
SEC (%) 68.10 40.00 0.0106
Amiodarone (%) 66.70 61.50 0.3321
J final (J) 91.95±30.10 97.78±36.06 0.2617
IRAF (%) 06.25 00.00 0.0991
IV AAD (%) 12.50 19.23 0.2220
APC (%) 59.57 50.00 0.2184
Bradycardia (%) 06.67 0.000 0.0961
MMP-9 (ng/mL) 124.28±75.80 121.58±40.60 0.4348
SDF-1α (ng/mL) 3.242±1.24 3.88±0.80 0.0105
TGF-β (ng/mL) 13.38±8.15 13.61±11.93 0.4652
Pro-ANP (nmol/L) 4.92±4.36 6.68±4.09 0.0477
hs-CRP (ng/mL) 4.29±11.20 4.01±12.68 0.4616
Time to recurrence
 (days) 
51.17±106.58 0.00±0.00 0.0086
AF: atrial fibrillation, CV: cardioversion, LA: left atrium, EF: ejec-
tion fraction, SEC: spontaneous echo contrast, J final: final CV en-
ergy (J), IRAF: immediate recurrence of AF after CV, AAD: anti-ar-
rhythmic drug, APC: atrial premature contractions, MMP-9: matrix 
metalloproteinase-9, SDF-1α: stromal cell derived factor-1α, TGF-
β: transforming growth factor-β, ANP: atrial natriuretic peptide, 
hs-CRP: high sensitive-C reactive protein 
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ence rate of AF after successful CV were not affected 
by LA size. Although the serological parameters were 
not different between the two groups, MMP-9 (139.6
±49.97 ng/mL vs. 107.78±65.15 ng/mL, p=0.0285) 
and SDF-1α (3.76±1.26 ng/mL vs. 3.24±0.99 ng/mL, 
p=0.0261) were significantly higher in patients with 
LA ≥48 mm than in those with LA <48 mm.  
 
Discussion 
 
In the present study, we prospectively explored pre-
dictors for failure of CV and recurrence of AF after sys-
temic electrical CV. We found that post-CV recurrence 
of AF commonly occurred in patients aged >60 years 
and low SDF-1α. High plasma levels of TGF-β pre-
dicted failure of electrical CV. Pre-determination of pre-
dictors for failure of CV or recurrence of AF after suc-
cessful CV might be useful for clinical decisions on rhy-
thm control strategies and for increasing our underst-
anding of the pathophysiology of AF. 
 
Serological factors predicting atrial fibrillation re-
currence after cardioversion 
In this study, a low plasma level of SDF-1α was an 
independent risk factor for AF recurrence after success-
ful CV. The chemokine SDF-1α has been shown to play 
a key role in hematopoietic or endothelial progenitor 
cell trafficking in the myocardial ischemia model,13-15) and 
the non-ischemic titrated cardiac injury model during 
catheter ablation of AF.16) However, the role of SDF-1α 
has been poorly explored in the pathophysiology of AF. 
Goette et al.17) report that SDF-1α levels are higher in 
PeAF than PAF or controls, and SDF-1α plays some role 
in the restitution of hematopoietic progenitor cells after 
failed CV. The reason for the high recurrence of AF in 
patients with low plasma levels of SDF-1α remains to be 
studied. Although it has been reported that high levels 
of hs-CRP are associated with an increased risk of re-
currence of AF,12)18) our data and data of Conway et al.19) 
failed to prove its predictive value in the clinic. The plas-
ma level of hs-CRP may be associated with the perman-
ence of AF related to systemic inflammation or proth-
rombotic status.20) 
 
Left atrium size and recurrence of atrial fibrillation 
after cardioversion 
The pathophysiology of AF is heterogeneous, and, 
like heart failure, includes various kinds of heart dise-
ase.21) Like the diversity of AF pathophysiology, the 
factors related to failed CV or recurrence after success-
ful CV might be widespread. An enlarged LA may re-
flect the degree of structural remodeling and LA pres-
Table 3. Comparison of patients in whom AF recurred within 2
weeks or after 2 weeks of successful CV 
 
ERAF 
(≤2 weeks) 
(n=22) 
LRAF 
(>2 weeks) 
(n=26) 
p 
Male (%) 81.00 81.00 0.4938
Age (years) 62.82±9.86 59.27±8.20 0.1666
LA size (mm) 46.77±4.40 45.68±6.27 0.2571
EF mean (%) 48.07±13.62 49.62±15.43 0.3606
SEC (%) 63.64 72.00 0.2748
J final (J) 96.50±34.68 85.0±27.39 0.1190
IRAF (%) 04.54 07.70 0.3309
IV AAD (%) 13.64 11.54 0.4156
APC (%) 68.19 52.00 0.1345
Bradycardia (%) 04.76 08.33 0.3205
MMP-9 (ng/mL) 109.84±73.19 137.92±77.74 0.1399
SDF-1α (ng/mL) 3.25±1.31 3.24±1.21 0.4871
TGF-β (ng/mL) 12.92±7.63 13.82±8.80 0.3741
Pro-ANP (nmol/L) 4.48±4.53 5.30±4.26 0.2629
hs-CRP (ng/mL) 1.69±2.67 6.33±14.59 0.0961
Time to recurrence 
 (days) 
8.67±4.16 85.5±134.71 0.0062
LA: left atrium, EF: ejection fraction, SEC: spontaneous echo con-
trast, J final: final CV energy (J), IRAF: immediate recurrence of AF 
after CV, AAD: anti-arrhythmic drug, APC: atrial premature con-
tractions, MMP-9: matrix metalloproteinase-9, SDF-1α: stromal 
cell derived factor-1α, TGF-β: transforming growth factor-β, ANP:
atrial natriuretic peptide, hsCRP: high sensitive-C reactive protein, 
CV: cardioversion, AF: atrial fibrillation 
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Post-CV days A B
Fig. 1. Kaplan-Meier curves suggest a higher recurrence rate of AF after successful CV in patients aged >60 years (A) and SDF-1α ≤3.0 
ng/mL (B). AF: atrial fibrillation, CV: cardioversion. 
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sure, and is one of the predictors for recurrence after 
RFCA of AF.22) However, LA diameter was not related 
to the failure of CV or recurrence of AF in this study 
or in other previous studies.10)23) With this in mind, 
one may ask why the meaning of LA diameter is dif-
ferent after electrical CV and RFCA. First, anti-arrhy-
thmic drugs were maintained after CV, but stopped 
within the 3rd month after RFCA in most institutes.22) 
Second, CV does not change atrial critical mass, but 
RFCA reduces it, which contains multiple reentries.21) 
Third, the risk of recurrence after AF ablation is high 
in patients with an enlarged LA because of the poten-
tial conduction gap on the long distance of linear abla-
tion or non-pulmonary vein foci.25) Fourth, patient se-
lection bias also contributes. In contrast, the mean LA 
diameter was 45.5 mm in this study, whereas LA di-
mensions >65 mm have been reported to be associated 
with AF recurrence after CV.24) We previously reported 
that poor mechanical reserve of the LA appendage pre-
dicts AF recurrence after CV,11) and prolonged atrial 
stunning after electrical CV is also related to poor 
clinical outcomes.26) Therefore, mechanical function of 
the atria may be more important in clinical outcomes 
after CV than morphological changes in the atria.  
 
The roles of upstream therapy  
Although approximately 50% of patients who are 
successfully cardioverted initially experience AF recurr-
ence within the first month after CV,5)6) anti-arrhythmic 
drugs24) and upstream medical therapy are effective in 
preventing this. Nakashima et al.27) first suggested the 
potential role of angiotensin II inhibitors for prevent-
ing atrial electrical and structural remodeling, and Ma-
drid et al.28) proved its effect in a prospective randomiz-
ed clinical study in patients with AF after electrical CV. 
ACE inhibitors29) and statins30) also play roles in the in-
hibition of AF recurrence after CV. These upstream ther-
apies may reduce the recurrence rate of AF after elec-
trical CV by preventing atrial structural remodeling. 
 
Limitations 
The patients included in this study were a highly se-
lected group chosen for their rhythm control; and the 
number of patients was limited. The exclusion of pa-
tients with large atria (bigger than 55 mm) may influ-
ence the outcomes related to LA size. The peripheral 
blood samples may only partially reflect the remote pro-
cess in the atria. Although we used anti-arrhythmic drugs 
in all patients before and after CV, the proportion tak-
ing amiodarone was 60.5%. In this study, mean age 
was higher in patients with recurrence after CV, and old 
age with low regenerating power may partially affect 
the low plasma level of SDF-1α. However, the low plas-
ma level of SDF-1α was still a statistically significant 
predictor for AF recurrence even after adjustment for 
age by Cox regression analysis {hazard ratio (HR) 0.443, 
CI: 0.245-0.803, p=0.007}. Although SDF-1α has been 
known to be related to stem cell homing and inflamma-
tory processes, the mechanism underlying it effect on 
the recurrence of AF is beyond our purpose and remains 
to be studied. 
 
Conclusion 
A high level of TGF-β was associated with failed CV. 
Post-CV recurrence was more common in patients aged 
>60 and low SDF-1α levels. However, LA size did not 
predict recurrence after CV. These predictors for AF 
recurrence after CV might provide additional informa-
tion in clinical decisions for rhythm vs. rate control and 
RFCA vs. repeated CV, in addition to increasing our 
understanding of the pathophysiology of AF.  
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